Presentation of positive key ovarian cancer data with Zejula at ESMO

9 September 2022

The Phase III PRIMA (ENGOT-OV26/GOG-3012) study showing that Zejula (niraparib) maintained a sustained and clinically meaningful progression-free survival (PFS) benefit as a maintenance therapy in patients with first-line ovarian cancer following a response to platinum-based chemotherapy, UK pharma major GSK (LSE: GSK) announced today.

Importantly, said GSK, this benefit was sustained across all biomarker subgroups, including BRCAm, HRd and HRp. Results from the updated efficacy analysis will be presented at the 2022 European Society for Medical Oncology (ESMO) Annual Meeting (September 9-13). Zejula was acquired by GSK along with its buy of US drugmaker Tesaro for $5.1 billion in 2018. The drug is already marketed and generate sales of £395 million in 2021, and is seen as one of GSK’s growth drivers.

After a median three and a half years follow up, this ad hoc analysis showed:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK